Paper Details

  1. Home
  2. Paper Details

[Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma：A Systematic Evaluation].

Author: LuoTao, XiaHai-Long

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Carfilzomib significantly improves survival in multiple myeloma patients compared to traditional treatments, without increasing the incidence of peripheral neuropathy. However, the incidence of cardiotoxicity appears to be higher. The overall response rate (ORR) was 93% and the 1-year progression-free survival (PFS) rate was 93%.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy and safety of carfilzomib in the treatment of multiple myeloma (MM). METHODS: Computer was used to search PubMed, EMbase, Cochrane library and MEDLINE databases for carfilzomib treatment of MM. Clinical features and results were extracted and meta-analysis was pe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.19746/j.cnki.issn.1009-2137.2019.06.029

データ提供：米国国立医学図書館（NLM）

Carfilzomib: A Promising Weapon in the Fight Against Multiple Myeloma

Multiple myeloma, a cancer of the plasma cells, presents a formidable challenge to healthcare professionals. This study delves into the efficacy and safety of carfilzomib, a new drug with potential to revolutionize the treatment of multiple myeloma. The authors meticulously review a collection of studies, analyzing the clinical outcomes and side effects associated with carfilzomib therapy.

A Powerful Ally in the Battle Against Multiple Myeloma

The study reveals the remarkable effectiveness of carfilzomib in treating multiple myeloma. The authors report impressive response rates, including a high overall response rate and a significant improvement in progression-free survival. These findings suggest that carfilzomib can be a powerful ally in the fight against this challenging cancer.

Navigating the Side Effect Landscape

The study also highlights the importance of understanding the potential side effects of carfilzomib therapy. The authors note an increased risk of cardiotoxicity, emphasizing the need for careful monitoring and management of cardiovascular health in patients receiving this treatment. Despite this potential risk, the study underscores the overall benefit of carfilzomib therapy in improving patient outcomes.

Dr.Camel's Conclusion

This study offers a promising glimpse into the future of multiple myeloma treatment. The authors' meticulous analysis of carfilzomib therapy reveals its potential to significantly improve patient outcomes. While the risk of cardiotoxicity should be carefully considered, the overall benefits of carfilzomib therapy make it a valuable addition to the arsenal of treatments for this challenging cancer.

Date :
  1. Date Completed 2019-12-26
  2. Date Revised 2020-03-13
Further Info :

Pubmed ID

31839055

DOI: Digital Object Identifier

10.19746/j.cnki.issn.1009-2137.2019.06.029

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.